Skip to main content
AZR
NASDAQ Life Sciences

Q3 Loss Widens to $64.6M on $57.1M Non-Cash Warrant Charge; Cash Falls to $22M

Tom Rudovsky · Reported by Wiseek News
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.74
Mkt Cap
$53.269M
52W Low
$1.31
52W High
$8.75
52W Position info
185% above low
Off High info
57% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AZR has more than doubled off its 52-week low of $1.31.

Summary

Azora's Q3 2026 net loss widened to $64.6M, or $4.52 per share, from $1.8M, or $2.02 per share, a year earlier, but $57.1M of that was a non-cash warrant-liability charge, so the operating loss is far smaller than the headline number. Cash fell to $22.0M from $28.7M at June 30, 2026, a $6.7M quarterly burn, and the company says that funds its current plan excluding warrant proceeds. Up to roughly $32.4M in gross proceeds could come from investors electing to buy milestone warrants, but that funding is not assured. R&D expense rose to $1.8M from $0.5M as preclinical and toxicology work for AT177 ramps. The next hard milestone is the AT177 IND submission and Phase 1a start, both planned for H1 2027.

At the time of this announcement, AZR was trading at $3.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $1.31 to $8.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

AZR - Latest Insights